The Swiss Times - Swiss News in English

Pharmaceutical industry welcomes “barrier-free access” to the internal market

The pharmaceutical industry has welcomed the adoption of the negotiating mandate with the EU. The "Bilaterals III" secured barrier-free access to the EU internal market, access to skilled workers and participation in EU programs.

Stable relations with the EU are key for Switzerland's largest export industry, wrote the trade association Scienceindustries on X. And the industry association Interpharma emphasized in a press release that by entering into negotiations with the EU, the so-called Mutual Recognition Agreement (MRA) could be updated to reduce technical barriers to trade.

This is of great importance for the industry's exports and security of supply. In addition, the free movement of persons offers the pharmaceutical industry access to "urgently needed qualified specialists". This is because the national market is not large enough to meet the high demand.

Finally, Swiss participation in EU research programs would be secured in the long term, without which Switzerland would have lost its attractiveness as a research location.


Most Read

Huge Rain Falls in Certain Regions of Ticino

1 April 2024
Over 200 litres of rain and snow per square meter inundated Ticino and neighbouring areas during the Easter weekend.

Sunday, March 31 – Weekend Round-Up

31 March 2024
The top Swiss municipalities for cost of living, Switzerland's diplomatic approach on international issues, and the healthcare sector's challenges.

The Park Hyatt Zurich Has Been Sold

4 April 2024
Trinity Investments, Oaktree Capital Management, and UBS Asset Management acquire Park Hyatt Zurich.

Swiss Francs Will Lose Value Against The Euro This Year – BOA Analysis Claims

1 April 2024
US banks foresee the Swiss Franc reaching parity with the Euro this year, with further appreciation expected by 2025.

Stay in Touch!


Barry Callebaut Beats Market Trends with Sales Increase
10 April 2024
Zug Leads Swiss Purchasing Power: GfK Study Insights
9 April 2024